Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is one of the stocks under $1 that will explode.

As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has surged roughly 37% in 2026 so far, showcasing a strong share price momentum.

However, at the same time, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is facing near-term regulatory challenges amid this share momentum, with the FDA recommending a second Phase 3 trial for brilaroxazine in schizophrenia. On December 23, 2025, the company saw H.C. Wainwright reiterate a ‘Buy’ rating with a $4 price target. The firm described the FDA guidance as consistent with precedent in schizophrenia drug development, projecting regulatory submission in late 2027, with potential approval and launch in late 2028.

Meanwhile, Roth Capital revisited Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) the following day, reducing its price target to $1.50, while reiterating a ‘Buy’ rating, according to TheFly. The firm cited anticipated equity dilution required to fund the second Phase 3 study, estimated at $60-75 million. Roth Capital remains optimistic about brilaroxazine’s therapeutic potential and has adjusted expectations following the FDA decision.

Additionally, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shared a brief update on the publication of vocal biomarker findings from the RECOVER trial. The update reinforces brilaroxazine’s efficacy assessment for negative symptoms and the progress on ongoing clinical development.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is focused on developing CNS, respiratory, and metabolic therapies. Using a proprietary chemical genomics platform, the company is advancing its RP5063 (brilaroxazine) and RP1208 pipelines.

While we acknowledge the potential of RVPH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.